elvanse adult hart hylki 50 mg
takeda pharmaceuticals international ag ireland branch - lisdexamfetaminum dimesylate - hart hylki - 50 mg
elvanse adult hart hylki 70 mg
takeda pharmaceuticals international ag ireland branch - lisdexamfetaminum dimesylate - hart hylki - 70 mg
qaialdo
nova laboratories ireland limited - spironolactone - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 5.
volidax hart hylki 30 mg
teva b.v.* - lisdexamfetaminum dimesylate - hart hylki - 30 mg
volidax hart hylki 50 mg
teva b.v.* - lisdexamfetaminum dimesylate - hart hylki - 50 mg
volidax hart hylki 70 mg
teva b.v.* - lisdexamfetaminum dimesylate - hart hylki - 70 mg
elvanse adult hart hylki 20 mg
takeda pharmaceuticals international ag ireland branch - lisdexamfetaminum dimesylate - hart hylki - 20 mg
elvanse adult hart hylki 40 mg
takeda pharmaceuticals international ag ireland branch - lisdexamfetaminum dimesylate - hart hylki - 40 mg
elvanse adult hart hylki 60 mg
takeda pharmaceuticals international ag ireland branch - lisdexamfetaminum dimesylate - hart hylki - 60 mg
aclasta
sandoz pharmaceuticals d.d. - zoledronsýra - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - lyf til að meðhöndla beinsjúkdóma - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture, including those with a recent low-trauma hip fracture. meðferð beinbrot í tengslum við langtíma almenn sykurstera meðferð í tíðahvörf konur og menn á jókst hættan á beinbrot. meðferð gerðar voru á fyrirbyggjandi er sjúkdómur bein.